Cardiology MCQ 179: abciximab

Which of the following is not true about abciximab?

a) Glycoprotein IIb/IIIa blocker
b) Orally active
c) Monoclonal
d) Used as an ajunct in PCI


["Click here for the answer with explanation", "Correct Answer:"]

b) Orally active

Abciximab is an intravenous glycoprotein IIb/IIIa blocker which is a monoclonal antibody, useful as an adjunct in percutaneous coronary intervention when there is a thrombus load in the coronary artery. Glycoprotein IIb/IIIa is the receptor in the final common pathway for platelet activation.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>